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ABSTRACT Increasing concern over rising levels of antibiotic 
resistance amongst pathogenic bacteria has prompted significant 
research into developing efficacious alternatives to antibiotic 
Page 1 of 57
ACS Paragon Plus Environment






























































treatment. Previously, we have reported on the therapeutic 
activity of a dinuclear ruthenium (II) complex against pathogenic, 
multidrug resistant bacterial pathogens. Herein, we report that 
the solubility properties of this lead are comparable to those 
exhibited by orally available therapeutics, that - in comparison 
to clinically relevant antibiotics - it induces very slow evolution 
of resistance in the uropathogenic, therapeutically resistant, E. 
coli strain EC958 and this resistance was lost when exposure to 
the compound was temporarily removed. With the aim of further 
investigating the mechanism of action of this compound, the 
regulation of nine target genes relating to the membrane, DNA 
damage and other stress responses provoked by exposure to the 
compound was also studied. This analysis confirmed that the 
compound causes a significant transcriptional downregulation of 
genes involved in membrane transport and the tricarboxylic acid 
cycle. By contrast, expression of the chaperone protein-coding 
gene, spy, was significantly increased suggesting a requirement 
for repair of damaged proteins in the region of the outer membrane. 
The complex was also found to display activity comparable to that 
in E. coli in a range of other therapeutically relevant Gram-
negative pathogens.
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Over recent years, there has been a significant increase in 
bacterial infections that display multidrug resistance, leading to 
a concomitant increase in mortality rates.1–3 As last-line 
treatments such as carbapenems increasingly fail,3–6 antimicrobial 
resistance is rapidly becoming a global threat to public health 
and the economy.7–9 It has been estimated that by 2050 ten million 
lives per year and a cumulative $100 trillion of economic output 
will be lost due to the rise of drug-resistant infections.10
Escherichia coli strains are a significant cause of infection 
within clinical settings and are linked to high morbidity and 
mortality globally causing a wide range of infections including 
meningitis, pneumonia and bacteraemia.11 E. coli is highly 
prevalent in urinary tract infections and accounts for 80 % of all 
community acquired urinary tract infections.12,13 High antimicrobial 
resistance within uropathogenic E. coli (UPEC) strains is common; 
a study of antibiotic resistance in cases of urinary tract 
infections in Nigeria found that from a total of 137 E. coli 
isolates 36 % were resistant to ten out of 11 urine line 
antibiotics.14 
In this context, UPEC sequence type ST131 is an emerging pathogen 
of particular concern. Apart from being commonly resistant to 
fluoroquinolones, this strain produces the CTX-M extended spectrum 
beta lactamase that confers resistance to oxyimino-cephalosporins 
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and monobactams.15–18 Furthermore, CTX-M encoding genes are found 
on plasmids which frequently carry additional resistance genes. As 
a consequence, geographical variants commonly possess quinolone 
modifying enzymes that provide fluroquinolone resistance, as well 
as the enzymes carbapenemases and cephamycinases.19
As global concern increased, the USA surveillance programs SENTRY 
and MYSTIC estimated through extrapolation that ST131 accounted 
for approximately 17 % of all E. coli isolates, 44 % of all 
antimicrobial resistant isolates and around 68 % of 
fluoroquinolone resistant isolates.16,20. This is problematic as 
within the US fluroquinolones are prescribed as a first line 
treatment against urinary tract infections. Given these facts, it 
is unsurprising that - even when treated with standard antibiotic 
regimes - urinary tract infections caused by ST131 can dangerously 
progress into pyelonephritis and sepsis.21,22
With one third of women having a course of antibiotics to treat 
a urinary tract infection by the age of 2623 multidrug resistant 
uropathogenic bacteria are clearly a significant threat, with 
ST131 being at the forefront of concern. It is therefore apparent 
that urine line antibiotics are a pivotal tool in healthcare and, 
as they are quickly becoming less effective, it is crucial that 
novel treatment options are identified.24
Metal complexes are a class of compounds that demonstrated 
significant early promise as therapeutic leads but are 
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underdeveloped. As early as the 1950s, the Dwyer group reported 
that RuII polypyridyl complexes had potential as antimicrobials.25,26 
Their work demonstrated that increasing the lipophilicity of the 
parent [Ru(phen)3]2+ cation resulted in enhanced antimicrobial 
action, leading to a derivative that displayed promising activity 
against Gram-positive bacteria. However, due to the wide range of 
effective conventional antibiotics clinically available at that 
time, no further development of these distinctive leads occurred 
for decades.
In the last decade or so, due to the growing antibiotic resistance 
crisis, the use of metals as antimicrobials has been revisited,27–32 
with particular focus on the RuII systems, 28,33 although most of 
these newly reported systems still exhibit higher activities 
against Gram-positive bacteria. As part of a program to develop 
novel metal-complex-based imaging probes,34–36 therapeutics37–40 and 
phototherapeutics,41–45 we recently identified a series of dinuclear 
ruthenium (II) complexes that exhibit higher activity against 
Gram-negative species.46 Subsequent detailed studies involving 
several strains of Staphylococcus aureus indicated that the 
lowered activity against Gram-positive bacteria is due to the 
complexes binding to cell wall teichoic acids residues, leading to 
reduced internalization.47
Although these reports provided preliminarily insights into the 
mechanism of action of these new potential therapeutics, in this 
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study a deeper and more focused understanding of the antimicrobial 
activity of the main lead complex, 14+ (Figure 1) is developed. The 
complex was synthesized as a PF6, for biological studies anion 
metathesis was used to convert the complex into the Cl- salt form. 
Using the multidrug resistant uropathogenic strain of E. coli as 
a model Gram-negative pathogen quantitative PCR (qPCR) was used to 
monitor the regulation of key genes thought to be responsible for 
sensing and reacting to the presence of 14+, providing further 
insights into its mechanism of action. As we also find the complex 
displays solubility that is comparable with established orally 
available therapeutics, is active against a range of Gram-negative 
pathogens, and resistance towards it emerges only very slowly, 
these data further underlines its therapeutic potential.
Figure 1. Structure of the ruthenium (II) complex relevant to this 
report.
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Over the last two decades, largely as a consequence of high 
through-put screening and demand for structurally complex drug 
leads, poor aqueous solubility has increasingly become a limiting 
development factor in drug development; compounds with poor solubility 
present high attrition risks and increased drug development costs.48–50 As complex 14+ 
displays activity against Gram-negative pathogens, and it is known 
that solubility is a key criterion for oral availability of any 
drug lead,51 its solubility was assessed through kinetic 
turbidimetric stability assays (Figure 2).
Compound LogS Solubility/µM Result
14+ 1.138 13.7 Pass
Nicardipine 1.318 20.8 Pass
Figure 2. Kinetic turbidimetric solubility. The kinetic solubility 
of 14+ measured through turbidimetry and compared with a positive 
control nicardipine. Turbidimetry was measured at 7 controls (0.2 
– 100 µM) in DMSO (1 %). Samples were incubated for 5 minutes at 
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25 °C. Absorbance determined at 620 nm. N = 4 ± SD. Any complex 
with a solubility of <1 µM is considered insoluble and therefore 
fails the solubility assay.
Nicardipine - a drug used to treat high blood pressure and angina, 
that is frequently employed in drug metabolism and pharmacokinetic 
studies - was used as a positive control and it was found that 14+ 
exhibits solubility in the range of this control – see SI for 
details. Under the Biopharmaceutics Classification System provided 
by the FDA, which is used to predict intestinal drug absorption, 
[1]Cl4 is seen to be freely soluble52. As aqueous solubility is a 
major factor in the bioavailability of antimicrobial compounds; 
the high solubility of 14+ indicates that it is a good orally 
delivered drug candidate.
Resistance of Escherichia coli EC958 to clinical antibiotics
The uropathogenic E. coli strain EC958 used in this study is a 
sequence type ST131 isolate.  Due to the presence of the extended-
spectrum β-lactamase gene blaCTX-M-15 on its pEC958 virulence 
plasmid it has been designated as a Priority 1: Critical Pathogen 
by the World Health Organization that urgently requires new 
treatments.18 To confirm the categorization and antibiotic 
resistance profile of this EC958 clinical isolate, phenotypic 
testing of its sensitivity to several β-lactam antibiotics was 
carried out. These studies - which included a monobactam and 
different generations of cephalosporins, as well as various other 
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major groups of antibiotics - were accomplished through a 
standardized EUCAST disc diffusion assay (Table 1).53
The tests revealed that the strain shows resistance to all tested 
cephalosporins and the monobactam; aztreonam, thus confirming its 
Priority 1 categorization; however, it is still sensitive to 
carbapenems, tigecycline, fosfomycin and nitrofurantoin.
Table 1. EUCAST disc diffusion antibiotic sensitivity testing 
against E. coli strain EC958
Antibiotic Disk content 
(µg)
Mean zone 

















Tigecycline 15 23 ± 0 Sensitive
Monobactams
Aztreonam 30 19.5 ± 0.47 Resistant
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*Sensitivity or resistance determined by EUCAST breakpoint 
figures, 201954.#Sensitivity or resistance determined by EUCAST 
breakpoint figures, 201855
Growth and viability of growing E. coli strain EC958 cultures is diminished upon 
exposure to 14+
Having established the multidrug resistance properties of the 
model EC958 strain, we investigated its sensitivity to complex, 
14+. Previously, we determined that the minimal inhibitory 
concentration (MIC) of 14+ was 2.8 µM46, however the MIC is measured 
using very low turbidity cultures recently diluted from stationary 
phase. As treatment of most infections occurs when the bacterial 
load is already high and actively growing, we investigated what 
effects exposure to the compound had on actively growing cultures. 
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phase were injected with a range of concentrations of 14+ below and 
above the MIC were performed. As Figure 3 illustrates, very little 
effect on growth is observed within the first 30 minutes of 
exposure to the compound. Subsequently, growth in the presence of 
14+ becomes inhibited for at least 2.5 h and the extent of growth 
inhibition correlates with increasing concentration of the 
compound. After this period, there is some recovery at 
concentrations up to 1 µM, but above this concentration little 
recovery in growth is seen. To understand whether 14+ was affecting 
viability or causing bacteriostasis at these concentrations, 
viability assays were performed (Figure 3B). From 2 h post-
injection, a significant difference in viability is observed 
between untreated cultures and those exposed to 0.5 – 5 µM of 14+. 
In agreement with this data, fluorescence microscopy shows 
accumulation of the RuII complex between 20 and 120 minutes and a 
significant increase in fluorescence at the 60- to 120-minute 
timepoints, indicating further accumulation of the compound 
(Figure 3C). Increase in fluorescence intensity was measured using 
the integrated density measurement function on ImageJ. At 60 
minutes the average corrected total cell fluorescence (CTCF) for 
the cells was 9308.9, at 120 minutes the average CTCF for the cells 
was 29956.9. This is in agreement with previous findings indicating 
that ruthenium accumulates within the cell during this time.46
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Figure 3. Effect of 14+ concentration on the growth and viability 
of E. coli strain EC958 in glucose defined minimal medium (A) 
Cultures were grown to early-exponential phase at 37 °C and 150 
rpm shaking in 250 ml flasks with defined minimal medium containing 
glucose as the sole carbon source. Upon reaching an OD600 of ~0.4 
differing concentrations of 14+ (0 - 5 µM) were added to the 
cultures and growth was monitored at regular intervals. N ≥ 3 ± 
SEM. (B) Samples of the cultures described in (A) were removed and 
viable counts performed to determine the bactericidal effect of 
14+ at differing concentrations between 0 - 5  µM. N ≥ 3  ± SEM. 
Statistical significance (**) was determined with two-way ANOVA 
and Tukey’s multiple comparisons (p <0.05). (C) Localization of 
14+ in E. coli EC958 cells was visualized through structured 
(C)
0 min 20 min 60 min 120 min
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illumination microscopy at 0-, 20-, 60- and 120-min. Cells were 
imaged using the emission of 14+ on excitation at 450 nm using A568 
filter. After treatment with 0.8 μM 14+cells were washed with nitric 
acid before fixing with paraformaldehyde (4 %). Images were taken 
using a 1516 oil and SlowFadeTM Gold Antifade Mountant.
Evolution of resistance of E. coli strain EC958 to 14+
The potential of 14+ as a putative antimicrobial lead would be 
enhanced if therapeutic resistance does not develop rapidly, nor 
to a high degree. To investigate this, we serially passaged EC958 
cultures containing concentrations of 14+ at half the minimal 
inhibitory concentration for five weeks. The WT MIC in minimal 
media (1.5 µM) was used for initiation of the experiment, new MIC 
assays were undertaken each week and changes to 14+ concentrations 
were made if an MIC increase was observed to maintain the 0.5 x 
MIC concentration in the growing cultures (Figure 4).
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Figure 4. Evolution of 14+ resistance of E. coli strain EC958 in 
glucose defined minimal media. E. coli cultures were grown in 
liquid GDMM containing 0.5 x MIC of 14+, cultures were passaged 
every 24 h and weekly MIC’s were determined. Experiments were 
performed as biological duplicates and results displayed are 
weekly mean MIC results (N ≥ 3 ± SD for each biological repeat). 
Control samples (upward and downward facing triangles) were 
treated the same as test samples (●, □), except no compound was 
added. Two-Way ANOVA with Tukey’s multiple comparison test showed 
significant differences between the original WT cultures and both 
test cultures by week five and between the test and control 
cultures in week five (p < 0.0001).
Both independent cultures that were passaged in the presence of 
14+ showed a small increase in resistance over the first two weeks 
of exposure with the MIC increasing from 1.5 µM to 6.1 µM. A 
further increase in resistance was observed in one of the test 
cultures after five weeks of exposure (MIC: 12.5 µM) whereas 
resistance in the other test culture remained constant between 
weeks two and week five. Significant differences were found between 
both test cultures after five weeks exposure to 14+ compared with 
the initial MIC of the WT strain (p < 0.001). We observed a four- 
to eight-fold increase in MIC over the course of five weeks 
constant exposure to 14+. Additionally, tests were performed to 
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determine whether resistance would evolve to 14+ due to serial 
passage in the absence of the ruthenium complex. Figure 4 shows a 
minor increase in resistance to the compound in week five where 
14+ was omitted, however this is a small increase, suggesting 
exposure to the ruthenium complex is required to cause significant 
resistance to 14+.
Samples from all cultures were streaked weekly to check for 
morphological changes or contaminants. Cultures exposed to the RuII 
complex consistently showed different colony size and morphology 
when subsequently streaked onto rich media in the absence of 14+ 
(Figure S-1). This effect was transient, as re-streaking of the 
different sized colonies subsequently produced normal growth (data 
not shown). 
All cultures in the evolution experiment depicted in Figure 4 
were cryopreserved weekly. When cultures that had demonstrated a 
four- to eight-fold increase in MIC were revived from these frozen 
stocks and 14+ susceptibility was retested, the MIC was reduced to 
WT levels. This indicates that the strains may not have become 
resistant to 14+ via mutational change, instead it suggests that 
altered expression of resistance genes such as those coding for 
efflux pumps and modulated membrane permeability may be the cause 
of the small increase in resistance after prolonged exposure to 
14+. Upon re-streaking from resistant cryopreserved stocks, these 
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genes appear to revert to their pre-exposure expression levels, 
resulting in the reduction in MIC to the original value.
Transcriptomic analysis reveals that membrane repair plays a significant role 
in the response to 14+ exposure
To further study the effects of 14+ on E. coli strain EC958 its 
mechanism of action was probed through quantitative PCR. From the 
study on bacterial growth after exposure to a range of 
concentrations of 14+ illustrated in Figure 3, we determined that 
a final RuII complex concentration of 1.5 µM would allow gene 
expression to be accurately assessed. Significant cell death 
occurs within 60-minutes of treatment when a lethal dose of the 
compound is administered. We therefore monitored changes in gene 
expression at timepoints ranging from 20 to 120 minutes to 
determine whether early changes in the response to the compound 
are altered after continued exposure.
Cultures in glucose defined minimal media were grown in 
triplicate to early-exponential phase, after which samples of the 
culture were removed to act as the pre-exposure control. 
Subsequently, at each timepoint, post-exposure samples were 
removed from the culture, RNA was extracted, and the expression of 
selected genes was compared to a reference.
Prompted by our initial experiments indicating a dual mechanism 
of action of 14+,46 the nine target genes selected for study have 
functional roles in membrane permeability/stability and DNA repair 
and a qPCR analysis was performed at all timepoints to assess 
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expression of these genes after exposure to 14+. The reference gene 
hcaT was selected for this study as it is a well-defined, 
constitutively expressed, gene under many conditions and showed no 
significant change in expression in whole-transcriptome analyses 
of E. coli exposed to other ruthenium-based compounds.56 In these 
experiments, it was found that three of the nine genes tested 
showed significant changes in expression upon exposure to 14+ 
(Figure 5).
Figure 5. Relative E. coli gene expression levels of nine target 
genes after exposure to 14+ show effects on membrane permeability 
and protein repair. The qPCR expression profiles of nine genes 
after exposure to 1.5 µM 14+ are shown over a time course of 20- 
(black bars), 60- (grey bars) and 120-minutes (white bars). N ≥ 3 
± SEM. Expression levels were normalised against reference gene 
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hcaT. Dashed horizontal lines represent significant expression 
changes (≥ 2-fold change).
A steady decrease in expression of the ompF gene was observed 
across the time-course. This gene encodes a non-specific porin 
found within E. coli57 and its primary function is facilitate 
passive diffusion of small hydrophilic molecules, including 
tetracycline and fluoroquinolones, across the cell membrane.57,58 
Therefore, downregulation of this gene upon exposure to 14+ 
suggests an attempt by the cell to prevent uptake of the compound 
by reducing membrane permeability. However, exposure of a wild 
type E. coli strain and several porin knock-out mutants, including 
ompF and ompF-ompC deletions59  to 14+ showed no significant change 
in the minimal inhibitory or bactericidal concentrations (Figure 
S-2).
Raised expression of the chaperone gene spy was observed over the 
time-course, with initial rapid growth in expression slowly 
plateauing at a constant, increased level. These observations 
suggest that the Spy protein is rapidly required after exposure to 
14+. In Gram-negative bacteria, changes in external environment can 
potentially affect the periplasmic space, resulting in unfavorable 
conditions that cause proteins to aggregate and/or unfold and in 
these circumstances chaperones like Spy are vital in maintaining 
protein folding homeostasis.60,61
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A significant decrease in expression of the sdhA gene was observed 
after 120-minutes exposure to 14+. The succinate dehydrogenase 
flavoprotein subunit, encoded by the sdhA gene, is a key protein 
involved in the tricarboxylic acid cycle; generation of precursor 
metabolites and aerobic respiration. Genes coding for key 
components of aerobic respiration have previously shown to be 
highly downregulated in E. coli when treated with another 
ruthenium-containing compound.62
To determine the wider effects of exposure to 14+, three other 
genes were tested for changes in expression after exposure. These 
were; the yrbF gene that encodes for a component of an ATP-binding 
cassette transporter system that maintains lipid asymmetry in the 
outer membrane which can be disrupted by chemicals or assembly 
defects63, ibpA that encodes for a small heat shock protein that 
protects various proteins from thermal and oxidative stress64, and 
ycfR that encodes for a protein considered as both a biofilm 
regulator and multi-stress response protein whose expression 
increases as a result of multiple environmental changes65. However, 
the expression levels of none of these genes altered significantly 
(by two-fold or greater) upon exposure to 14+.
14+ shows antimicrobial activity of against different strains of pathogenic 
bacteria
Given that antimicrobial resistance is a serious problem across 
many species of pathogenic bacteria, and it is not always possible 
to know the identity of the infecting pathogen prior to initiating 
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treatment, it is important to understand the spectrum of activity 
of 14+. As our previous work has indicated that this complex appears 
to be more active in Gram-negative  bacteria,47 we explored its 
activity against a wider spectrum of multidrug and pandrug 
resistant E. coli strains as well as other Gram-negative pathogenic 
species– Table 2. The  E. coli strains include a KPC-producing 
(Klebsiella pneumonia carbapenase) E. coli2, an avian pathogenic 
E. coli, the E. coli EC958 strain (for comparison) and an 
antimicrobial testing control strain NCTC 12923. The other Gram-
negative pathogens included in this panel were clinical isolates 
of Pseudomonas aeruginosa, Salmonella kedougou, Shigella flexneri, 
Enterobacter hormaechei, Citrobacter koseri and Acinetobacter 
baumannii. Interestingly, the potent activity of 14+ against the 
control strain is retained in all the tested drug resistant 
strains, including carbapenem resistant pathogens, indicating its 
broad spectrum of activity.
Table 2. Minimum inhibitory concentration for 14+ demonstrate 







E. coli EC958 Multidrug resistant, 
clinical isolate
1.7
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P. aeruginosa Clinical isolate 1.9
K. pneumoniae Clinical isolate 1.6
S. kedougou Clinical isolate 1.4
S. flexneri Clinical isolate 4.2
E. hormaechei Clinical isolate 1.7
C. koseri Clinical isolate 1.1
A. baumannii Clinical isolate 1.6
Discussion
Examination of the antibiotic susceptibility profile of this 
uropathogenic E. coli strain demonstrates its significant 
multidrug resistance. Current treatment recommendations for 
uncomplicated urinary tract infections where antibiotic therapy is 
indicated include the administration of nitrofurantoin, 
trimethoprim / sulfamethoxazole, fluoroquinolones, fosfomycin or 
oral β-lactam agents. Clinicians are guided in their choice of 
treatment by local susceptibility patterns of E. coli and other 
uropathogens as strain specific antimicrobial susceptibility 
profiles are usually not determined 66. The EC958 strain tested 
here showed resistance to several β-lactam antibiotics and both 
fluoroquinolones tested, however both nitrofurantoin and 
fosfomycin were shown to be effective (Table 2). Much of the 
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antibiotic resistance profile demonstrated herein is expected when 
interrogating the whole genome sequence of this organism 18. 
Totsika et al, report the presence of the pEC958 plasmid in this 
strain that contains multiple antibiotic resistance genes. The 
presence of tetA and tetR found on the pEC958 plasmid provide 
resistance to early members of the tetracyclines, however do not 
confer resistance to the third-generation tigecycline tested here. 
67 68 Resistance to the fluoroquinolones and aminoglycosides can be 
explained by the presence of aac(6')-Ib-cr, encoding an 
aminoglycoside acetyltransferase capable of causing resistance to 
aminoglycosides and fluoroquinolones via modification of the drug. 
69 70 71 However, interestingly no obvious genomic explanation for 
rifampicin resistance could be found. Resistance to rifampicin 
commonly occurs via mutation of the rpoB gene and resistance is 
easily evolved. 72 Therefore our strain of EC958 may be a variant 
of the one described previously18,73 that has acquired this 
mutation. With no apparent carbapenem resistance genes in the 
genome sequence and EC958 displaying sensitivity to all four types 
tested this drug class would provide a good treatment option in 
the case of disease progression from EC958 causing a urinary tract 
infection to pyelonephritis and bloodstream infection.
Given the extensive multidrug resistance of this, and many other 
bacterial pathogens, new antimicrobial leads that do not readily 
succumb to evolving resistance are urgently needed. The rate at 
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which resistance to an antimicrobial arises is dependent on its 
mechanism of action and whether single or multiple changes are 
required for significant resistance to arise. We compared the 
resistance changes of EC958 when exposed to 14+ with literature 
reports of resistance evolution in E. coli exposed to commonly 
used antibiotics. One study showed that continuous exposure to 
levofloxacin caused E. coli to increase resistance to this 
antibiotic by 16-fold within the first 24 h of exposure and 64-
fold after 14 days. The mechanism of resistance was identified as 
mutation of targets of the fluoroquinolone and changes in membrane 
permeability.74 Resistance to fluroquinolones such as levofloxacin 
only requires a single point mutation in DNA gyrase to emerge, so 
the rapid increase observed in this study is not surprising. A 
separate study exposed E. coli to three antibiotics: trimethoprim, 
chloramphenicol and doxycycline, in different evolution 
experiments. Trimethoprim, an antibiotic commonly used to treat 
urinary tract infections, showed a consistent increase in 
resistance of around 1,680-fold after 20 days of exposure. 
Increases of 870- and 10-fold were observed against 
chloramphenicol and doxycycline respectively 75. One further study 
found that clinical resistance could be evolved in previously 
susceptible uropathogenic E. coli strains to ciprofloxacin, 
amoxacillin and aminoglycosides by as little as one, two and three 
to five day(s) of passage respectively76. Thus, the evolution of 
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resistance to 14+ is slow in comparison to many clinically available 
antibiotics. The slow and low level resistance gains of EC958 
against 14+ may be due to its multi-mechanism mode of action which 
targets both the cell membrane and intracellular targets46,47. 
Therefore, it seems likely that resistant isolates would take 
significantly longer to arise, further adding promise to 14+ as a 
therapeutic tool.
In addition to gaining further insight into the potential for 
resistance to the RuII complex, it is important to fully understand 
how 14+ causes bacterial growth inhibition and cell death. Figure 
2 demonstrates that very little impact on growth is observed within 
the first 30 minutes post-injection of the compound. This is in 
agreement with previous stimulated emission depletion imaging that 
identified a 20-minute period when compound accumulation at cell 
membranes occurs before localisation at cell poles 46. Alexa Fluor 
NHS-ester-405 counterstaining experiments also demonstrated that 
membrane damage is not present within at least the first five 
minutes of exposure to 14+ with subsequent bacterial inner and 
outer membrane damage identified 60 minutes post-exposure. 14+.
To gain insight into how EC958 senses and responds to the presence 
of 14+ at a transcriptomic level, we selected nine genes associated 
with the proposed targets of the complex; the bacterial membranes 
and DNA, to better understand the bacterial response to membrane 
damage and to determine whether DNA is a secondary target.
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We observed a steady decrease in expression of ompF upon exposure 
to 14+, OmpF is a non-specific porin found within E. coli57. This 
porin allows passive diffusion of small hydrophilic charged 
molecules and antibiotics including tetracyclines and 
fluoroquinolones across the cell membrane 57. As downregulation of 
ompF causes resistance to multiple antibiotics, this change in 
gene expression may be a cause of the transient resistance gained 
during prolonged exposure to 14+ (Figure 2)77. However, with upper 
limits for molecular weight; the cut-off for porins of E. coli is 
around 600 Da.78 As the molecular weight of 14+ is considerably 
larger than this, OmpF mediated transport is unlikely to be a 
mechanism of passage into the bacterial cell46. Aside from the 
generalized porins, there are solute-specific facilitated 
diffusion channels through the outer membrane into the periplasm 
that allow solutes to bypass the porin-specific size and charge 
requirements, 14+ may utilize one of these routes to gain entry to 
the cell78. 
An increase in expression of the spy gene was observed upon 
exposure to 14+. Spheroplast protein Y (Spy) is a non-ATP dependent 
periplasmic chaperone, vital in maintaining the homeostasis of 
protein folding under cellular stress 60,61. In Gram-negative 
bacteria, such as EC958, changes in external environment impact 
the periplasmic space, resulting in unfavorable conditions for 
proteins leading to aggregation and unfolding. In these conditions 
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spy expression is upregulated to help prevent unfolding and 
aggregation and to re-fold substrates without ATP. Stresses that 
have been found to cause induction in the spy gene include ethanol, 
indole, tannins and metals such as zinc, copper and other 
ruthenium-based complexes with differing mechanistic 
actions62,79,80. In this case, the upregulation of spy upon treatment 
with 14+ is likely due to the compound damaging the bacterial 
membrane and altering the conditions of the periplasmic space. 
Therefore, this increase in expression may be an attempt by the 
cell to regain the balance of protein aggregation and unfolding in 
this region. The expression of spy is controlled by the two-
component systems CpxAR and BaeSR; both responsible for regulation 
of the envelope stress response. Accumulation of 14+ at the poles 
of the cell is demonstrated herein (Figure 3C) and supports 
previous findings46. This transcriptomic data provides further 
evidence that the membrane is a major site of activity for this 
compound, which appears to selectively target and damage bacterial 
membranes but not to damage mammalian cells nor demonstrate 
significant toxicity in animal models at similar concentrations46. 
This is an important finding in the selectivity and therapeutic 
potential of 14+.
After two hours of exposure to 14+ a significant decrease in the 
expression of sdhA was observed. The succinate dehydrogenase 
flavoprotein subunit A (SdhA) is part of the succinate 
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dehydrogenase enzyme complex, bound to the inner surface of the 
cytoplasmic membrane its primary functions are to catalyze the 
oxidation of succinate to fumarate in the citric acid cycle and to 
participate in the aerobic electron transport pathway to generate 
energy for the cell by oxidative phosphorylation 81. At two hours 
14+ has penetrated the membranes of E. coli and entered the cell 
where it could potentially cause significant intracellular damage, 
therefore it is  likely that treated bacteria downregulate various 
metabolic pathways in order to conserve energy and prevent the 
production of further potentially harmful species, causing the 
reduction in sdhA expression. 
We previously showed that 14+ binds intracellular targets at 60-
minutes46,47. To decipher whether this binding could cause damage 
to bacterial DNA we monitored the regulation of three genes that 
would be upregulated as a response to DNA damage and the SOS 
response: recA, recN and umuC. No significant change was observed 
in any of these genes suggesting that the bacteria did not produce 
an SOS response. Therefore, at the low compound concentrations 
used, DNA damage is unlikely to be a target for 14+ in E. coli. The 
gene expression levels of three further proteins were examined 
upon exposure to 14+. The protein expressed by ycfR is a biofilm 
regulator. It is a multi-stress response protein, expression of 
which increases as a result of environmental changes.65 The gene 
yrbF encodes for a component of an ATP-binding cassette transporter 
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system, which is one mechanism that the cell may use to maintain 
lipid asymmetry in the outer membrane when chemically disrupted63. 
Finally, the heat shock protein gene, IbpA protects various 
substrates and proteins when the cell undergoes thermal and 
oxidative stress64. Interestingly, no significant change in gene 
expression was observed for these genes after exposure to 14+ 
indicting that exposure to the complex results in a relatively 
specific disruption to cellular function.
This gene expression data provides further evidence to support 
the hypothesis that the bacterial cell membrane is a significant 
target of 14+ with disruption to the stability of periplasmic 
proteins being a major stressor for the cell. The pathogen screen 
for sensitivity to this ruthenium complex showed significant 
activity against several Gram-negative species, each of these 
species also contain homologues of the spy and sdhA genes, so it 
is likely that these pathogens will elicit similar responses upon 
exposure (Table 2). However, the outer membrane proteins expressed 
by the Gram-negative pathogens differ significantly between the 
species tested, with P. aeruginosa containing a porin of unusually 
low permeability (OprF) and A. baumannii containing an E. coli 
OmpA homologue (OmpAAB). These porins are thought to contribute to 
the intrinsic antibiotic resistance of these species, but as shown 
in Table 2 they do not appear to contribute to resistance against 
14+. Recently, Smitten et al examined the differing activity of 14+ 
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against Gram positive bacterial pathogens47 demonstrating that the 
level and type of teichoic acids present within the Gram positive 
cell wall has a significant impact on the antimicrobial activity 
of the compound. Testing antimicrobial activity of 14+ against 
several Gram negative bacterial species has confirmed the broad-
spectrum activity of this compound against Gram negative 
pathogens, including clinical isolates and multi-drug resistant 
strains (Table 2) further demonstrating the potential of this 
compound for future use as a therapeutic in the fight against 
antimicrobial resistant infections.
Conclusions
As with previous studies with 14+ and the EC958 pathogenic strain 
of E. coli, it was found the compound is highly potent against 
several pathogenic E. coli strains and other Gram-negative 
pathogens. Although a small rise in resistance was observed over 
five weeks of exposure, the slow rate and relatively low level of 
evolution in comparison to that of clinically available organic 
antibiotics makes 14+ a strong potential candidate for 
antimicrobial therapeutics. In addition, the good kinetic 
solubility indicates the compound will have good bioavailability 
and could be used as an oral antimicrobial. Transcriptomic analysis 
suggests that 14+ does cause damage both to the inner and outer 
membrane, resulting in unfavorable, stressful conditions in the 
periplasmic space. Together this work adds to the growing volume 
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of research supporting the hypothesis that this class of RuII 
complexes can be developed into effective antimicrobial drugs.
 Future research will further consider the potential emergence 
of resistance to this lead with a particular focus on mechanisms 
of cellular entry and efflux and any proteins capable of binding 
to the complex making it unavailable to bind other more vulnerable 
targets within the cell. Such studies will facilitate the 
circumvention of these mechanism if they prove to be potential 
routes of resistance.
Materials and Methods
Bacterial strains and culture conditions
Strains used in this study are listed in Table 1, the primary 
strain used was a CTX-M-15 type extended spectrum β-lactamase 
(EBSL)-producing clinical isolate E. coli EC958 (ST131)73. Bacteria 
were routinely grown aerobically at 37 °C in either Mueller-Hinton 
broth (Sigma Aldrich, UK) or defined minimal medium with glucose 
as the sole carbon source (GDMM) as described previously 46. Prior 
to experiments, bacterial starter cultures were prepared by 
inoculating the appropriate liquid medium with colonies from a 
fresh agar plate and incubation at 37 °C with shaking at 180 rpm 
for approximately 18 h. Where necessary cultures were 
cryopreserved in a sterile suspension of 25 % glycerol : 75 % 
Mueller-Hinton broth (v/v) at -80 °C.
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Preparation and storage of 14+
The 14+ compound was synthesised as previously described46. Stocks 
solutions of 14+ were made to a concentration of 5 mg ml-1 in sterile 
deionised water and were stored at room temperature protected from 
light.
Disc Diffusion Assay
Disk diffusion assays were performed in accordance with European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines53. After incubation the diameter of the zones of 
inhibition were measured and compared to EUCAST breakpoints.54,55
Determination of minimal inhibitory concentrations
MICs of 14+ were determined via the standard broth-dilution method 
in 96-well microtiter plates in glucose defined minimal media. The 
MIC was evaluated using 2-fold decreasing concentrations of the 
compound between 50 to 0.09 µM against starter cultures diluted to 
an OD600 of 0.05 − 0.1 (equivalent to a 0.5 McFarland standard). 
Plates were incubated at 37 °C for 16 - 20 h after which the 
presence or absence of growth in each well was observed to 
determine the minimal inhibitory concentration of 14+ for each of 
the strains tested.
Bacterial growth and viability measurements
Cultures were incubated in 250 ml conical flasks from 2.5 % 
starter cultures of E. coli EC958 in 30 ml GDMM media at 37 °C 
with shaking at 150 rpm. Once cultures reached an early exponential 
growth phase (OD600 ~0.4) 14+ was added at the appropriate final 
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concentrations and growth monitored at regular intervals for the 
subsequent five hours. Viability was measured for samples 
harvested at the relevant time points after serial dilution in 
phosphate-buffered saline by plating 10 µl aliquots on Mueller-
Hinton agar and incubation overnight at 37 °C.
Structured illumination microscopy
Samples were prepared and analysed as previously described 46. 
Briefly, E. coli cultures were grown in GDMM to an OD600 of 0.3-
0.4 and 14+ was added to a final concentration of 0.8 µM. Samples 
were incubated for 0-, 20-, 60- and 120-min before washing with 
nitric acid and fixation with paraformaldehyde (4 %). Localization 
of 14+ in E. coli EC958 cells was visualized through structured 
illumination microscopy using a 1516 oil and SlowFadeTM Gold 
Antifade Mountant. Cell fluorescence was measured using ImageJ by 
selecting a cell and measuring area, integrated density and mean 
grey value. Background fluorescence was determined and corrected 
for in each image. Four cells were measured per image. The 
corrected total cell fluorescence was calculated by CTCF = 
Integrated Density – (Area of selected cell X mean fluorescence of 
background readings). 
Evolution of resistance assays
After determination of the MIC for 14+, a 1 % inoculum of starter 
culture incubated in GDMM was added to 10 ml of GDMM. Compound was 
then added where appropriate to the culture at 0.5 times the MIC 
allowing growth of the strain in sub-MIC exposure. Control cultures 
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were set up in the same manner in the absence of 14+. Cultures were 
incubated at 37 °C and 180 rpm for 24 h, after which a 1 % inoculum 
from this culture was used to inoculate a fresh tube of GDMM + / 
- 14+. This process was repeated every 24 h of the lifetime of the 
experiment. Each week cultures were cryopreserved and re-tested 
for their MIC with the amount of compound added to subsequent 
cultures adjusted as required to maintain a 0.5 times MIC.
Quantitative PCR analysis
Cells were grown as described above in GDMM. At the designated 
times pre- and post- injection of a final concentration of 1.5 µM 
14+, 5 ml samples of culture were removed into 10 ml volumes of RNA 
Protect (Qiagen, UK) in triplicate for RNA stabilisation. RNA was 
extracted using the RNeasy Mini Kit from Qiagen according to 
manufacturer’s instructions and qPCR performed as previously 
described82 using a QuantStudio™ 3 Real Time PCR System (Applied 
Biosystems). Primers used for PCR can be found in supplementary 
information.
Kinetic Turbidimetric Solubility assays
Aqueous solubility was measured using a high throughput 
turbidimetric assay. A 10 mM stock of each compound (nicardipine 
hydrochloride and 14+) were made up in DMSO. This stock was diluted 
in phosphate buffered saline (PBS pH 7.4) to give concentrations 
(µM): 0.4, 2, 4, 20, 40, 100 and 200. The final DMSO concentration 
= 1 %. Each concentration was plated out in triplicate. The 
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solutions were incubated for 2 h at 37 °C then the absorbance read 
on a plated reader at 620 nm.
Statistical analyses
GraphPad Prism v7.05 software was used for statistical analysis 
tests include one-way ANOVA, two-way ANOVA With Turkey’s multiple 
comparison tests and Welch’s T-test.
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